NYXH News & Events

Nyxoah announced an investment in Belgium to further scale its manufacturing capacity. In addition to its existing contract manufacturing operations in the United States, the company will expand its manufacturing footprint in Wallonia. As part of this investment, Nyxoah has signed an agreement with LegiaPark that will support Nyxoah's product development activities and the creation of a nearly 2,000 square meters manufacturing facility, including a cleanroom, developed in collaboration with ABN Cleanroom Technology.

Reports preliminary FY25 gross revenue EUR 11M. "Our first full quarter of U.S. commercialization post-FDA approval resulted in strong momentum," commented Olivier Taelman, Nyxoah's CEO. "Our first U.S. patients are experiencing great results; we have a waiting list for additional surgeon training and patients scheduled for implants. Global revenue exceeded EUR 10 million due to the strong U.S. launch and further international geographical expansion. We have established a strong foundation for sustained growth and look forward to expanding Genio adoption in the U.S. throughout 2026."